Liraglutide

A GLP-1 receptor agonist with a fatty-acid chain enabling self-association and albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-daily administration. It is also referred to as Saxenda, Victoza. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.

FDA approved. The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.

~13 h, subcutaneous. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.

Marketed as ready-to-use multi-dose prefilled pens; refrigerate before first use, then store per label and protect from light. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.

The approved label carries 2 transcribed notes covering other oral medications, insulin and insulin secretagogues. Each one restates a numbered section of the label rather than offering advice of our own. Absence of a topic means nothing was transcribed, not that a combination is safe.